Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 5, 2023 20:25 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 213.296 | $0.00 Strike: $146.51 | $0.00 |
DisclosureSEC source: 0001062993-23-014479 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,733.709 Underlying: Common Stock · 213.296 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| June 30, 2023 Filed Jul 12, 2023 20:03 UTC Amendment | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 247.423 | $0.00 Strike: $146.51 | $0.00 |
DisclosureSEC source: 0001062993-23-014835 · form4a.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767.836 Underlying: Common Stock · 247.423 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:17 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-018903 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,840 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:17 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $217.39 | $1,233,716.06 |
DisclosureSEC source: 0001127602-23-018903 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,930 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $214.86 to 219.21. The price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:17 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-018903 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:10 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-015838 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,515 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:10 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $232.10 | $1,317,190.77 |
DisclosureSEC source: 0001127602-23-015838 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,930 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $231.02 - $232.78. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 30.2388 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:10 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-015838 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 950.779 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011211 · form4.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,762.937 Underlying: Common Stock · 950.779 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $136.73 | $0.00 |
DisclosureSEC source: 0001062993-23-011211 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,520.413 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 20.376 phantom stock units accrued on April 28, 2023 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-013145 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,190 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:59 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $224.23 | $1,272,526.25 |
DisclosureSEC source: 0001127602-23-013145 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.99 - $225.525. The price reported above reflects the weighted average sale price. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-013145 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 243.172 | $0.00 Strike: $128.51 | $0.00 |
DisclosureSEC source: 0001062993-23-008492 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000.037 Underlying: Common Stock · 243.172 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 21.839 phantom stock units accrued on January 31, 2023 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-010519 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,865 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $206.95 | $1,174,450.90 |
DisclosureSEC source: 0001127602-23-010519 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $205.82 - $208.24. The price reported above reflects the weighted average sale price. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-010519 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:23 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-005517 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,540 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $214.83 | $1,219,143.79 |
DisclosureSEC source: 0001127602-23-005517 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $213.07 - $215.35. The price reported above reflects the weighted average sale price. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:23 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-005517 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:28 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-001650 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,215 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:28 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $224.36 | $1,273,268.54 |
DisclosureSEC source: 0001127602-23-001650 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $220.59 - $225.635. The price reported above reflects the weighted average sale price. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:28 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-001650 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 21:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 246.122 | $0.00 Strike: $126.97 | $0.00 |
DisclosureSEC source: 0001062993-23-000261 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,735.026 Underlying: Common Stock · 246.122 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 24.354 phantom stock units accrued on October 31, 2022 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 19:53 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-027648 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,890 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 19:53 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $215.63 | $1,223,727.49 |
DisclosureSEC source: 0001127602-22-027648 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $214.14 - $220.37. The price reported above reflects the weighted average sale price. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 19:53 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-027648 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:32 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 33,239 | $224.40 | $7,458,831.60 |
DisclosureSEC source: 0001127602-22-026363 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:32 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 56,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026363 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,139 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 00:55 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 36,569 | $224.58 Strike: $224.58 | $8,212,666.02 |
DisclosureSEC source: 0001127602-22-026096 · form4.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,569 Underlying: ResMed Common Stock · 36,569 shares Expires 2029-11-16 F1 · kind: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:52 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-025860 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,565 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $224.64 | $1,274,837.11 |
DisclosureSEC source: 0001127602-22-025860 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,024 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.13 $226.34. The price reported above reflects the weighted average sale price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:52 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-025860 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:39 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,038 | $225.18 | $684,096.84 |
DisclosureSEC source: 0001127602-22-025657 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,024 F3 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:39 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,233 | $225.18 | $728,006.94 |
DisclosureSEC source: 0001127602-22-025657 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,062 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:39 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,359 | $225.18 | $531,199.62 |
DisclosureSEC source: 0001127602-22-025657 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,295 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:56 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,880 | $220.83 | $1,077,650.40 |
DisclosureSEC source: 0001127602-22-025406 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 0 F3 · price: This transaction was executed in multiple trades at prices ranging from $220.67 $220.97. The price reported above reflects the weighted average sale price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:56 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025406 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 4,880 F2 · kind: Gift of shares transferred from The Lisette and Michael Farrell Family Trust, Mr. Farrell retains dispositive power over the gifted shares. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:56 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025406 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 4,090 F1 · kind: Gift of shares transferred to The Lisette and Michael Farrell Foundation, Mr. Farrell retains dispositive power over remaining shares. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:18 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-024077 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,240 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:18 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $214.58 | $1,217,723.34 |
DisclosureSEC source: 0001127602-22-024077 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,570 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $213.43 to $215.62. The price reported above reflects the weighted average sale price. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:18 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-024077 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:25 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 293.62 | $0.00 Strike: $106.43 | $0.00 |
DisclosureSEC source: 0001062993-22-020326 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,464.55 Underlying: Common Stock · 293.62 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 23.702 phantom stock units accrued on July 29, 2022 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:19 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-022621 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,915 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:19 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $228.96 | $1,299,336.08 |
DisclosureSEC source: 0001127602-22-022621 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,570 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $225.93 to $233.73. The price reported above reflects the weighted average sale price. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:19 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-022621 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:06 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 17,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021421 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,570 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-021156 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,590 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,675 | $238.09 | $1,351,165.86 |
DisclosureSEC source: 0001127602-22-021156 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.22 to $240.41. The price reported above reflects the weighted average sale price. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-021156 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.